Dr. Black on the Developments in the Field of Immunotherapy for Bladder Cancer

Peter Black, MD
Published: Friday, Aug 25, 2017



Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses future developments being made in the field of immunotherapy for patients with bladder cancer.

Immunotherapy still holds the majority of interest in bladder cancer, but there is more to treatments than just immunotherapy, states Black.

The clinical trial field has become very complex as things move upstream, explains Black. There are adjuvant trials before and after radical cystectomy, and trials in non-muscle invasive bladder cancer.



Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses future developments being made in the field of immunotherapy for patients with bladder cancer.

Immunotherapy still holds the majority of interest in bladder cancer, but there is more to treatments than just immunotherapy, states Black.

The clinical trial field has become very complex as things move upstream, explains Black. There are adjuvant trials before and after radical cystectomy, and trials in non-muscle invasive bladder cancer.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x